Compare Amphastar Pharmaceuticals Inc (AMPH) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Materials Select Sector SPDR Fund — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Materials Select Sector SPDR Fund trades at $53.25. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | XLB | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | — |
52-Week High | $30.81 | $53.62 |
52-Week Low | $16.87 | $42.23 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
XLB trades at $52.86, up 1.32% today, with a bullish technical signal from moving averages and neutral oscillators. The materials sector benefits from AI infrastructure demand and strong Q2 earnings momentum, as noted by Zacks Investment Research on August 6, 2026. A dividend of $0.19 is scheduled for June 2026, while recent news highlights sector resilience amid geopolitical shifts.
Outlook is positive due to cyclical recovery and AI-driven demand, but risks include pricing pressures and economic sensitivity. Analysts see limited near-term upside after recent gains, with a hold rating common. Institutional interest remains strong, supporting stability amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
